MAP2K7 and central nervous system cancer: Multiple case reports have shown some clinical efficacy of BRAF inhibitors (vemurafenib, dabrafenib) either alone or in combination with MEK inhibitors (trametinib) in BRAF-mutated glioma patients [4].